An introspective update on the influence of miRNAs in breast carcinoma and neuroblastoma chemoresistance

Genetics Research International

Volumn 2014, Issue , 2014, Pages

  Carta, Alessia ^a   Chetcuti, Rachel ^a   Ayers, Duncan ^a,b  

^a UNIVERSITY OF MALTA   (Malta)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; ETOPOSIDE; MICRORNA; MICRORNA 10A; MICRORNA 125B; MICRORNA 128; MICRORNA 137; MICRORNA 140; MICRORNA 200A; MICRORNA 200B; MICRORNA 200C; MICRORNA 203; MICRORNA 205; MICRORNA 21; MICRORNA 210; MICRORNA 221; MICRORNA 222; MICRORNA 27A; MICRORNA 298; MICRORNA 29A; MICRORNA 30C; MICRORNA 31; MICRORNA 34; MICRORNA 34A; MICRORNA 451; MICRORNA 487A; MICRORNA 93; UNCLASSIFIED DRUG;

BREAST CARCINOGENESIS; BREAST CARCINOMA; CANCER INCIDENCE; CANCER STAGING; CHROMOSOME 11Q; CHROMOSOME 17Q; CHROMOSOME 1P; CHROMOSOME DELETION; CHROMOSOME LOSS; CLINICAL FEATURE; DISEASE ASSOCIATION; DOWN REGULATION; DRUG RESISTANCE; GENE AMPLIFICATION; HUMAN; METASTASIS; NEUROBLASTOMA; ONCOGENE C MYB; ONCOGENE NEU; PLOIDY; REVIEW; RNA INTERFERENCE; TUMOR SUPPRESSOR GENE; UPREGULATION;

EID: 84940404830     PISSN: 20903154     EISSN: 20903162     Source Type: Journal    
DOI: 10.1155/2014/743050     Document Type: Review

References (169)

1. E. Farber, "The multistep nature of cancer development," Cancer Research, vol. 44, no. 10, pp. 4217-4223, 1984.
2. D. Hanahan and R. A. Weinberg, "Hallmarks of cancer: the next generation," Cell, vol. 144, no. 5, pp. 646-674, 2011.
3. R. A. Weinberg, "The retinoblastoma protein and cell cycle control," Cell, vol. 81, no. 3, pp. 323-330, 1995.
4. R. Weinberg, The Biology of Cancer, Garland Science, 2nd edition, 2013.
5. D. Naor, R. V. Sionov, and D. Ish-Shalom, "CD44: structure, function, and associationwith the malignant process," Advances in Cancer Research, vol. 71, pp. 241-319, 1997.
6. J. A. Logan, M. E. Kelly, D. Ayers, N. Shipillis, G. Baier, and P. J. R. Day, "Systems biology and modeling in neuroblastoma: practicalities and perspectives," Expert Review of Molecular Diagnostics, vol. 10, no. 2, pp. 131-145, 2010.
7. N. Bouck, V. Stellmach, and S. C. Hsu, "How tumors become angiogenic," Advances in Cancer Research, vol. 69, pp. 135-174, 1996.
8. C. Osborne, P. Wilson, and D. Tripathy, "Oncogenes and tumor suppressor genes in breast cancer: potential diagnostic and therapeutic applications," Oncologist, vol. 9, no. 4, pp. 361-377, 2004.
9. A. Jemal, F. Bray, M. M. Center, J. Ferlay, E. Ward, and D. Forman, "Global cancer statistics," CA Cancer Journal for Clinicians, vol. 61, no. 2, pp. 69-90, 2011.
10. H. L. Martin, L. Smith, and D. C. Tomlinson, "Multidrug-resistant breast cancer: current perspectives," Breast Cancer: Targets and Therapy, vol. 6, pp. 1-13, 2014.
11. X. Hu, H. M. Stern, L. Ge et al., "Genetic alterations and oncogenic pathways associated with breast cancer subtypes," Molecular Cancer Research, vol. 7, no. 4, pp. 511-522, 2009.
12. A. Gschwind, O. M. Fischer, and A. Ullrich, "The discovery of receptor tyrosine kinases: targets for cancer therapy," Nature Reviews Cancer, vol. 4, no. 5, pp. 361-370, 2004.
13. E. K. Rowinsky, "Signal events: cell signal transduction and its inhibition in cancer," The Oncologist, vol. 8, no. 3, pp. 5-17, 2003.
14. Y. Yarden and M. X. Sliwkowski, "Untangling the ErbB signalling network," Nature Reviews Molecular Cell Biology, vol. 2, no. 2, pp. 127-137, 2001.
15. M. A. Olayioye, R. M. Neve, H. A. Lane, and N. E. Hynes, "The ErbB signaling network: receptor heterodimerization in development and cancer," The EMBO Journal, vol. 19, no. 13, pp. 3159-3167, 2000.
16. J. W. Lee, Y. H. Soung, S. H. Seo et al., "Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas," Clinical Cancer Research, vol. 12,no. 1, pp. 57-61, 2006.
17. J.-P. Borg, S. Marchetto, A. Le Bivic et al., "ERBIN: a basolateral PDZ protein that interacts with the mammalian ERBB2/HER2 receptor," Nature Cell Biology, vol. 2, no. 7, pp. 407-414, 2000.
18. H. Lodish, A. Berk, L. S. Zipursky, P. Matsudaira, D. Baltimore, and J. Darnell, Molecular Cell Biology, W.H. Freeman, 4th edition, 2000, http://www.ncbi.nlm.nih.gov/books/NBK21475/.
19. "BRCA1 and BRCA2: Cancer Risk and Genetic Testing Fact Sheet," National Cancer Institute, 2014, http://www.cancer.gov/cancertopics/factsheet/Risk/BRCA.
20. BRCA1 - Breast Cancer 1, Early Onset-Genetics Home Reference, 2014, http://ghr.nlm.nih.gov/gene/BRCA1.
21. Genetics, BreastCancer.org, 2014, http://www.breastcancer.org/risk/factors/genetics.
22. "Hereditary Breast Ovarian Cancer Syndrome (BRCA1/BRCA2) - Information About Cancer - Stanford Cancer Center - Stanford Medicine," Stanford Medicine, 2014, http://cancer.stanford.edu/information/geneticsAndCancer/types/herbocs.html.
23. N. Petrucelli, M. B. Daly, and G. L. Feldman, BRCA1 and BRCA2 Hereditary Breast and Ovarian Cancer, 1998, http://www.ncbi.nlm.nih.gov/books/NBK1247/.
24. E. M. Rosen, S. Fan, R. G. Pestell, and I. D. Goldberg, "BRCA1 gene in breast cancer," Journal of Cellular Physiology, vol. 196, no. 1, pp. 19-41, 2003.
25. A.-M. Martin and B. L. Weber, "Genetic and hormonal risk factors in breast cancer," Journal of the National Cancer Institute, vol. 92, no. 14, pp. 1126-1135, 2000.
26. R. Scully, S. F. Anderson, D. M. Chao et al., "BRCA1 is a component of the RNA polymerase II holoenzyme," Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 11, pp. 5605-5610, 1997.
27. L. C. Hsu and R. L. White, "BRCA1 is associated with the centrosome during mitosis," Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 22, pp. 12983-12988, 1998.
28. D. R. Kellogg, M. Moritz, and B. M. Alberts, "The centrosome and cellular organization," Annual Review of Biochemistry, vol. 63, pp. 639-674, 1994.
29. J. S. Larson, J. L. Tonkinson, and M. T. Lai, "A BRCA1 mutant alters G2-M cell cycle control in human mammary epithelial cells," Cancer Research, vol. 57, no. 16, pp. 3351-3355, 1997.
30. M. E. Thompson, R. A. Jensen, P. S. Obermiller, D. L. Page, and J. T. Holt, "Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression," Nature Genetics, vol. 9, no. 4, pp. 444-450, 1995.
31. A. R. Venkitaraman, "Functions of BRCA1 and BRCA2 in the biological response to DNA damage," Journal of Cell Science, vol. 114, no. 20, pp. 3591-3598, 2001.
32. J. Chen, D. P. Silver, D. Walpita et al., "Stable interaction between the products of the BRCA1 and BRCA2 tumor suppressor genes in mitotic and meiotic cells," Molecular Cell, vol. 2, no. 3, pp. 317-328, 1998.
33. R. Scully, J. Chen, A. Plug et al., "Association of BRCA1 with Rad51 in mitotic and meiotic cells," Cell, vol. 88, no. 2, pp. 265-275, 1997.
34. C. M. Radding, "Helical interactions in homologous pairing and strand exchange driven by recA protein," The Journal of Biological Chemistry, vol. 266, no. 9, pp. 5355-5358, 1991.
35. A. Shinohara, H. Ogawa, and T. Ogawa, "Rad51 protein involved in repair and recombination in S. cerevisiae is a RecA-like protein," Cell, vol. 69, no. 3, pp. 457-470, 1992.
36. J. M. Gudas, T. Li, H. Nguyen, D. Jensen, F. J. Rauscher III, and K. H. Cowan, "Cell cycle regulation of BRCA1 messenger RNA in human breast epithelial cells," Cell Growth and Differentiation, vol. 7, no. 6, pp. 717-723, 1996.
37. J. M. Gudas, H. Nguyen, T. Li, and K. H. Cowan, "Hormone-dependent regulation of BRCA1 in human breast cancer cells," Cancer Research, vol. 55, no. 20, pp. 4561-4565, 1995.
38. J. V. Rajan, M. Wang, S. T. Marquis, and L. A. Chodosh, "Brca2 is coordinately regulated with Brca1 during proliferation and differentiation in mammary epithelial cells," Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 23, pp. 13078-13083, 1996.
39. R. Scully and D. M. Livingston, "In search of the tumour-suppressor functions of BRCA1 and BRCA2," Nature, vol. 408, no. 6811, pp. 429-432, 2000.
40. Breast Cancer Genes - Live Well - NHS Choices, http://www.nhs.uk/Livewell/Breastcancer/Pages/Breastcancergenes.aspx.
41. "Breast cancer genes: Cancer Research UK: CancerHelp UK," http://www.cancerresearchuk.org/cancer-help/type/breast-cancer/about/risks/breast-cancer-genes.
42. Signs and symptoms of breast cancer, American Cancer Society, 2014, http://www.cancer.org/cancer/breastcancer/moreinformation/breastcancerearlydetection/breast-cancer-early-detection-signs-symptoms-br-ca.
43. Breast Cancer, Cancer.Net, 2014, http://www.cancer.net/cancer-types/breast-cancer/diagnosis.
44. What Is Breast Cancer? BreastCancer.org, 2013, http://www.breastcancer.org/symptoms/understand-bc/what-is-bc.
45. B. K. B. Hirata, J. M. M. Oda, R. L. Guembarovski, C. B. Ariza, C. E. C. D. Oliveira, and M. A. E. Watanabe, "Molecular markers for breast cancer: prediction on tumor behavior," Disease Markers, vol. 2014, Article ID 513158, 12 pages, 2014.
46. World Cancer Research Fund International, Breast Cancer Statistics, 2008, http://www.wcrf.org/int/cancer-facts-figures/data-specific-cancers/breast-cancer-statistics.
47. Breast Cancer Statistics Worldwide, Worldwide Breast Cancer, 2009, http://www.worldwidebreastcancer.com/learn/breast-cancer-statistics-worldwide/.
48. Tumor Grade Fact Sheet - National Cancer Institute [Internet], 2013, http://www.cancer.gov/cancertopics/factsheet/detection/tumor-grade.
49. "Howis breast cancer staged?" 2014, http://www.cancer.org/cancer/breastcancer/detailedguide/breast-cancer-staging.
50. N. Olsson, P. Carlsson, P. James et al., "Grading breast cancer tissues using molecular portraits," Molecular and Cellular Proteomics, vol. 12, no. 12, pp. 3612-3623, 2013.
51. Treatment & Side Effects, BreastCancer.org, 2013, http://www.breastcancer.org/treatment.
52. K. M. Tien, Madame Curie Bioscience Database, Landes Bioscience, Austin, Tex, USA, 2000.
53. A. Ahmad, "Pathways to breast cancer recurrence," ISRN Oncology, vol. 2013, Article ID 290568, 16 pages, 2013.
54. A. Brewster, G. N. Hortobagyi, K. R. Broglio et al., "Residual risk of breast cancer recurrence 5 years after adjuvant therapy," Journal of the National Cancer Institute, vol. 100, no. 16, pp. 1179-1183, 2008.
55. V. Fodale, M. Pierobon, L. Liotta, and E. Petricoin, "Mechanism of cell adaptation: when and how do cancer cells develop chemoresistance?" Cancer Journal, vol. 17, no. 2, pp. 89-95, 2011.
56. M. A. Hayat, Neuroblastoma, Springer, 2011.
57. A. M. Davidoff, "Neuroblastoma," Seminars in Pediatric Surgery, vol. 21, no. 1, pp. 2-14, 2012.
58. J. M. Maris, M. D. Hogarty, R. Bagatell, and S. L. Cohn, "Neuroblastoma," The Lancet, vol. 369, no. 9579, pp. 2106-2120, 2007.
59. J. M. Maris and K. K. Matthay, "Molecular biology of neuroblastoma," Journal of Clinical Oncology, vol. 17, no. 7, pp. 2264-2279, 1999.
60. T. Monclair, G. M. Brodeur, P. F. Ambros et al., "The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report," Journal of Clinical Oncology, vol. 27, no. 2, pp. 298-303, 2009.
61. "The Neuroblastoma Society - Fighting Childhood Cancer," http://www.nsoc.co.uk/.
62. G. M. Brodeur, "Neuroblastoma: biological insights into a clinical enigma," Nature Reviews Cancer, vol. 3, no. 3, pp. 203-216, 2003.
63. W. B. London, R. P. Castleberry, K. K. Matthay et al., "Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group," Journal of Clinical Oncology, vol. 23, no. 27, pp. 6459-6465, 2005.
64. J. L. Young Jr., L. G. Ries, E. Silverberg, J. W. Horm, and R. W. Miller, "Cancer incidence, survival, and mortality for children younger than age 15 years," Cancer, vol. 58, no. 2, pp. 598-602, 1986.
65. M. J. Horner, L. A. G. Ries, M. Krapcho et al., "SEER Cancer Statistics Review 1975-2006-Previous Version-SEER Cancer Statistics," 2008, http://seer.cancer.gov/archive/csr/1975-2006/.
66. Board ADAME, Neuroblastoma, 2012, http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0002381/.
67. P. F. Ambros, I. M. Ambros, G. M. Brodeur et al., "International consensus for neuroblastoma molecular diagnostics: Report from the International Neuroblastoma Risk Group (INRG) Biology Committee," British Journal of Cancer, vol. 100, no. 9, pp. 1471-1482, 2009.
68. G. M. Brodeur, G. S. Sekhon, and M. N. Goldstein, "Chromosomal aberrations in human neuroblastomas," Cancer, vol. 40, no. 5, pp. 2256-2263, 1977.
69. G. M. Brodeur, R. C. Seeger, M. Schwab, H. E. Varmus, and J. M. Bishop, "Amplification of N -myc in untreated human neuroblastomas correlates with advanced disease stage," Science, vol. 224, no. 4653, pp. 1121-1124, 1984.
70. Y. P. Mossé, M. Laudenslager, L. Longo et al., "Identification of ALK as a major familial neuroblastoma predisposition gene," Nature, vol. 455, no. 7215, pp. 930-935, 2008.
71. G. Ramsay, L. Stanton, M. Schwab, and J. M. Bishop, "Human proto-oncogene N-myc encodes nuclear proteins that bind DNA," Molecular and Cellular Biology, vol. 6, no. 12, pp. 4450-4457, 1986.
72. M. Yoshimoto, S. R. C. De Toledo, E. M. Monteiro Caran et al., "MYCN gene amplification: identification of cell populations containing double minutes and homogeneously staining regions in neuroblastoma tumors," The American Journal of Pathology, vol. 155, no. 5, pp. 1439-1443, 1999.
73. J. Charron, J.-F. Gagnon, and J.-F. Cadrin-Girard, "Identification of N-myc regulatory regions involved in embryonic expression," Pediatric Research, vol. 51, no. 1, pp. 48-56, 2002.
74. E. F. Attiyeh, W. B. London, Y. P. Mossé et al., "Chromosome 1p and 11q deletions and outcome in neuroblastoma," The New England Journal of Medicine, vol. 353, no. 21, pp. 2243-2253, 2005.
75. C. Guo, P. S. White, M. J. Weiss et al., "Allelic deletion at 11q23 is common in MYCN single copy neuroblastomas," Oncogene, vol. 18, no. 35, pp. 4948-4957, 1999.
76. How Chemotherapy Works [Internet], "American Cancer Society," 2013, http://www.cancer.org/treatment/treatmentsandsideeffects/treatmenttypes/chemotherapy/chemotherapyprinciplesanin-depthdiscussionofthetechniquesanditsroleintreatment/chemotherapy-principles-how-chemo-works.
77. C. R. James, J. E. Quinn, P. B. Mullan, P. G. Johnston, and D. P. Harkin, "BRCA1, a potential predictive biomarker in the treatment of breast cancer," Oncologist, vol. 12, no. 2, pp. 142-150, 2007.
78. American Cancer Society, Cancer Medicine 6, edited by D. W. Kufe, J. F. Holland, E. Frei, BC Decker, Hamilton, Canada, 6th edition, 2003.
79. D. Ayers and A. Nasti, "Utilisation of nanoparticle technology in cancer chemoresistance," Journal of Drug Delivery, vol. 2012, Article ID 26569, 12 pages, 2012.
80. B. Rexer and C. Arteaga, "Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implications," Critical Reviews in Oncogenesis, vol. 17, no. 1, pp. 1-16, 2012.
81. J. Zhou, "Multi-Drug Resistance in Cancer," 2010, http://www.springerlink.com/index/10.1007/978-1-60761-416-6.
82. M. F. Ullah, "Cancer multidrug resistance (MDR): a major impediment to effective chemotherapy," Asian Pacific Journal of Cancer Prevention, vol. 9, no. 1, pp. 1-6, 2008.
83. G. Batist, A. Tulpule, B. K. Sinha, A. G. Katki, C. E. Myers, and K. H. Cowan, "Overexpression of a novel anionic glutathione transferase in multidrug-resistent human breast cancer cells," The Journal of Biological Chemistry, vol. 261, no. 33, pp. 15544-15549, 1986.
84. X.-Y. Hao, M. Widersten, M. Ridderström, U. Hellman, and B. Mannervik, "Co-variation of glutathione transferase expression and cytostatic drug resistance in HeLa cells: establishment of class Mu glutathione transferase M3-3 as the dominating isoenzyme," Biochemical Journal, vol. 297, no. 1, pp. 59-67, 1994.
85. T. R. Wilson, D. B. Longley, and P. G. Johnston, "Chemoresistance in solid tumours," Annals of Oncology, vol. 17, supplement 10, pp. x315-x324, 2006.
86. K. E. Allen and G. J. Weiss, "Resistance may not be futile: microRNA biomarkers for chemoresistance and potential therapeutics," Molecular Cancer Therapeutics, vol. 9, no. 12, pp. 3126-3136, 2010.
87. M. M. Gottesman, "Mechanisms of cancer drug resistance," Annual Review of Medicine, vol. 53, no. 1, pp. 615-627, 2002.
88. F.-S. Liu, "Mechanisms of chemotherapeutic drug resistance in cancer therapy - a quick review," Taiwanese Journal of Obstetrics and Gynecology, vol. 48, no. 3, pp. 239-244, 2009.
89. J. R. Riordan, K. Deuchars, N. Kartner, N. Alon, J. Trent, and V. Ling, "Amplification of P-glycoprotein genes in multidrug-resistant mammalian cell lines," Nature, vol. 316, no. 6031, pp. 817-819, 1985.
90. R. Clarke, F. Leonessa, and B. Trock, "Multidrug resistance/P-glycoprotein and breast cancer: review and meta-analysis," Seminars in Oncology, vol. 32, supplement 2, pp. S9-S15, 2005.
91. N. S. Wind and I. Holen, "Multidrug resistance in breast cancer: fromin vitromodels to clinical studies," International Journal of Breast Cancer, vol. 2011, Article ID 967419, 12 pages, 2011.
92. G. J. R. Zaman, M. J. Flens, M. R. van Leusden et al., "The human multidrug resistance-associated protein MRP is a plasmamembrane drug-efflux pump," Proceedings of the National Academy of Sciences of the United States of America, vol. 91, no. 19, pp. 8822-8826, 1994.
93. S. Zhou, J. D. Schuetz, K. D. Bunting et al., "The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype," Nature Medicine, vol. 7, no. 9, pp. 1028-1034, 2001.
94. Y. G. Assaraf, "The role of multidrug resistance efflux transporters in antifolate resistance and folate homeostasis," Drug Resistance Updates, vol. 9, no. 4-5, pp. 227-246, 2006.
95. "MicroRNA and RNA Interference, miRNAs Research," Molecular Devices. 2013, http://www.moleculardevices.com/Applications/Molecular-Function/RNAi.html.
96. K. R. Kutanzi, O. V. Yurchenko, F. A. Beland, V. F. Checkhun, and I. P. Pogribny, "MicroRNA-mediated drug resistance in breast cancer," Clinical Epigenetics, vol. 2, no. 2,pp. 171-185, 2011.
97. Z. Liang, H. Wu, J. Xia et al., "Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1," Biochemical Pharmacology, vol. 79, no. 6, pp. 817-824, 2010.
98. H. Guo, N. T. Ingolia, J. S. Weissman, and D. P. Bartel, "Mammalian microRNAs predominantly act to decrease target mRNA levels," Nature, vol. 466, no. 7308, pp. 835-840, 2010.
99. L.-A. MacFarlane and P. R. Murphy, "MicroRNA: biogenesis, function and role in cancer," Current Genomics, vol. 11, no. 7, pp. 537-561, 2010.
100. MicroRNA - Why Study It and How, 2010, http://www.sabiosciences.com/pathwaymagazine/pathways7/microrna.php.
101. X. Cai, C. H. Hagedorn, and B. R. Cullen, "Human microRNAs are processed from capped, polyadenylated transcripts that can also function as mRNAs," RNA, vol. 10, no. 12, pp. 1957-1966, 2004.
102. R. I. Gregory, T. P. Chendrimada, N. Cooch, and R. Shiekhattar, "Human RISC couples microRNA biogenesis and posttranscriptional gene silencing," Cell, vol. 123, no. 4, pp. 631-640, 2005.
103. M. T. Bohnsack, K. Czaplinski, and D. Görlich, "Exportin 5 is a RanGTP-dependent dsRNA-binding protein that mediates nuclear export of pre-miRNAs," RNA, vol. 10, no. 2, pp. 185-191, 2004.
104. R. Yi, Y. Qin, I. G. Macara, and B. R. Cullen, "Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs," Genes and Development, vol. 17, no. 24, pp. 3011-3016, 2003.
105. A. Grishok, A. E. Pasquinelli, D. Conte et al., "Genes and mechanisms related to RNA interference regulate expression of the small temporal RNAs that control C. elegans developmental timing," Cell, vol. 106, no. 1, pp. 23-34, 2001.
106. J. Martinez, A. Patkaniowska, H. Urlaub, R. Lührmann, and T. Tuschl, "Single-stranded antisense siRNAs guide target RNA cleavage in RNAi," Cell, vol. 110, no. 5, pp. 563-574, 2002.
107. S. Gu and M. A. Kay, "How do miRNAs mediate translational repression?" Silence, vol. 1, no. 1, article 11, 2010.
108. D. P. Bartel, "MicroRNAs: target recognition and regulatory functions," Cell, vol. 136, no. 2, pp. 215-233, 2009.
109. G. Meister, M. Landthaler, A. Patkaniowska, Y. Dorsett, G. Teng, and T. Tuschl, "Human Argonaute2 mediates RNA cleavage targeted by miRNAs and siRNAs," Molecular Cell, vol. 15, no. 2, pp. 185-197, 2004.
110. Q. Liu, T. A. Rand, S. Kalidas et al., "R2D2, a bridge between the initiation and effector steps of the Drosophila RNAi pathway," Science, vol. 301, no. 5641, pp. 1921-1925, 2003.
111. L. C. Cheng, M. Tavazoie, and F. Doetsch, "Stem cells: from epigeneticsto microRNAs," Neuron, vol. 46, no. 3, pp. 363-367, 2005.
112. L. He and G. J. Hannon, "MicroRNAs: small RNAs with a big role in gene regulation," Nature Reviews Genetics, vol. 5, no. 7, pp. 522-531, 2004.
113. P.-S. Chen, J.-L. Su, and M.-C. Hung, "Dysregulation of MicroRNAs in cancer," Journal of Biomedical Science, vol. 19, no. 1, article 90, 2012.
114. M. V. Iorio and C. M. Croce, "MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review," EMBO Molecular Medicine, vol. 4, no. 3, pp. 143-159, 2012.
115. G. A. Calin, C. Sevignani, C. D. Dumitru et al., "Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers," Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 9, pp. 2999-3004, 2004.
116. A. G. Bader, D. Brown, J. Stoudemire, and P. Lammers, "Developing therapeutic microRNAs for cancer," GeneTherapy, vol. 18, no. 12, pp. 1121-1126, 2011.
117. Y. Hua, N. Larsen, S. Kalyana-Sundaram, J. Kjems, A. M. Chinnaiyan, and M. E. Peter, "MiRConnect 2.0: identification of oncogenic, antagonistic miRNA families in three human cancers," BMC Genomics, vol. 14, no. 1, article 179, 2013.
118. S. Jiang, H. W. Zhang, M. H. Lu et al., "MicroRNA-155 functions as an oncomiR in breast cancer by targeting the suppressor of cytokine signaling 1 gene," Cancer Research, vol. 70, no. 8, pp. 3119-3127, 2010.
119. O. A. Elgamal, J.-K. Park, Y. Gusev et al., "Tumor suppressive function of mir-205 in breast cancer is linked to HMGB3 regulation," PLoS ONE, vol. 8, no. 10, Article IDe76402, 2013.
120. M. V. Lorio, P. Casalini, C. Piovan et al., "microRNA-205 regulates HER3 in human breast cancer," Cancer Research, vol. 69, no. 6, pp. 2195-2200, 2009.
121. L. Ma and R. A. Weinberg, "Micromanagers of malignancy: role of microRNAs in regulating metastasis," Trends in Genetics, vol. 24, no. 9, pp. 448-456, 2008.
122. L. Ma, J. Teruya-Feldstein, and R. A. Weinberg, "Tumour invasion and metastasis initiated by microRNA-10b in breast cancer," Nature, vol. 449, no. 7163, pp. 682-688, 2007.
123. X. Han, S. Yan, Z. Weijie et al., "Critical role of miR-10b intransforming growth factor-β1-induced epithelial-mesenchymal transition in breast cancer," Cancer Gene Therapy, vol. 21, no. 2, pp. 60-67, 2014.
124. M. Flahaut, R. Meier, A. Coulon et al., "The Wnt receptor FZD1 mediates chemoresistance in neuroblastoma through activation of the Wnt/β-catenin pathway," Oncogene, vol. 28, no. 23, pp. 2245-2256, 2009.
125. L. Bao, S. Hazari, S. Mehra, D. Kaushal, K. Moroz, and S. Dash, "Increased expression of P-glycoprotein and doxorubicin chemoresistance of metastatic breast cancer is regulated by miR-298," American Journal of Pathology, vol. 180, no. 6, pp. 2490-2503, 2012.
126. H. Zhu, H. Wu, X. Liu et al., "Role of MicroRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cells," Biochemical Pharmacology, vol. 76, no. 5, pp. 582-588, 2008.
127. L. N. Abdullah and E. K. Chow, "Mechanisms of chemoresistance in cancer stem cells," Clinical and Translational Medicine, vol. 2, no. 1, p. 3, 2013.
128. S. Fulda and K.-M. Debatin, "Apoptosis pathways in neuroblastoma therapy," Cancer Letters, vol. 197, no. 1-2, pp. 131-135, 2003.
129. M. Muzio, A. M. Chinnaiyan, F. C. Kischkel et al., "FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex," Cell, vol. 85, no. 6, pp. 817-827, 1996.
130. D. Ovcharenko, K. Kelnar, C. Johnson, N. Leng, and D. Brown, "Genome-scale microRNA and small interfering RNA screens identify small RNA modulators of TRAIL-induced apoptosis pathway," Cancer Research, vol. 67, no. 22, pp. 10782-10788, 2007.
131. F. Felicetti, M. C. Errico, L. Bottero et al., "The promyelocytic leukemia zinc finger-microRNA-221/-222 pathway controls melanoma progression through multiple oncogenic mechanisms," Cancer Research, vol. 68, no. 8, pp. 2745-2754, 2008.
132. D. Sayed, M. He, C. Hong et al., "MicroRNA-21 is a downstream effector of AKT that mediates its antiapoptotic effects via suppression of fas ligand," The Journal of Biological Chemistry, vol. 285, no. 26, pp. 20281-20290, 2010.
133. D. Kim, H. C. Dan, S. Park et al., "AKT/PKB signaling mechanisms in cancer and chemoresistance," Frontiers in Bioscience, vol. 10, pp. 975-987, 2005.
134. J. A. Chan, A. M. Krichevsky, and K. S. Kosik, "MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells," Cancer Research, vol. 65, no. 14, pp. 6029-6033, 2005.
135. R. Schickel, S.-M. Park, A. E. Murmann, and M. E. Peter, "miR-200c regulates induction of apoptosis through CD95 by targeting FAP-1," Molecular cell, vol. 38, no. 6, pp. 908-915, 2010.
136. R. Hamano, H. Miyata, M. Yamasaki et al., "Overexpression of miR-200c induces chemoresistance in esophageal cancers mediated through activation of the Akt signaling pathway," Clinical Cancer Research, vol. 17, no. 9, pp. 3029-3038, 2011.
137. H. Hermeking, "The miR-34 family in cancer and apoptosis," Cell Death and Differentiation, vol. 17, no. 2, pp. 193-199, 2010.
138. H. Hermeking, "p53 enters the microRNA world," Cancer Cell, vol. 12, no. 5, pp. 414-418, 2007.
139. G. T. Bommer, I. Gerin, Y. Feng et al., "p53-mediated activation of miRNA34 candidate tumor-suppressor genes," Current Biology, vol. 17, no. 15, pp. 1298-1307, 2007.
140. B. Song, Y. Wang, Y. Xi et al., "Mechanism of chemoresistance mediated by miR-140 in human osteosarcoma and colon cancer cells," Oncogene, vol. 28, no. 46, pp. 4065-4074, 2009.
141. I. Bray, K. Bryan, S. Prenter et al., "Widespread dysregulation of MiRNAs by MYCN amplification and chromosomal imbalances in neuroblastoma: association of miRNA expression with survival," PLoS ONE, vol. 4, no. 11, Article ID e7850, 2009.
142. Y. Chen and R. L. Stallings, "Differential patterns of microRNA expression in neuroblastoma are correlated with prognosis, differentiation, and apoptosis," Cancer Research, vol. 67, no. 3, pp. 976-983, 2007.
143. Y. Chen, Y. H. Tsai, Y. Fang, and S. H. Tseng, "Micro-RNA-21 regulates the sensitivity to cisplatin in human neuroblastoma cells," Journal of Pediatric Surgery, vol. 47, no. 10, pp. 1797-1805, 2012.
144. J. Buechner, J. R. Henriksen, B. H. Haug, E. Tømte, T. Flaegstad, and C. Einvik, "Inhibition of mir-21, which is up-regulated during MYCN knockdown-mediated differentiation, does not prevent differentiation of neuroblastoma cells," Differentiation, vol. 81, no. 1, pp. 25-34, 2011.
145. R. Singh and Y.-Y. Mo, "Role of microRNAs in breast cancer," Cancer Biology andTherapy, vol. 14, no. 3, pp. 201-212, 2013.
146. L. O'Driscoll and M. Clynes, "Biomarkers and multiple drug resistance in breast cancer," Current Cancer Drug Targets, vol. 6, no. 5, pp. 365-384, 2006.
147. W. Wu, Ed., MicroRNA and Cancer [Internet], Humana Press, Totowa, NJ, USA, 2011.
148. O. Kovalchuk, J. Filkowski, J. Meservy et al., "Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin," Molecular Cancer Therapeutics, vol. 7, no. 7, pp. 2152-2159, 2008.
149. M. H. Zhang, H. T. Man, X. Zhao, N. Dong, and S. Ma, "Estrogen receptor-positive breast cancer molecular signatures and therapeutic potentials (Review)," Bioscience Reports, vol. 2, no. 1, pp. 41-52, 2014.
150. T. Sorlie, C. M. Perou, R. Tibshirani et al., "Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications," Proceedings of the National Academy of Sciences of the United States of America, vol. 98,no. 19,pp. 10869-10874, 2001.
151. C. M. Perou and A.-L. Borresen-Dale, "Systems biology and genomics of breast cancer," Cold Spring Harbor Perspectives in Biology, vol. 3, no. 2, pp. 1-17, 2011.
152. A. H. Lund, "MiR-10 in development and cancer," Cell Death and Differentiation, vol. 17, no. 2, pp. 209-214, 2010.
153. S. P. McDermott and M. S. Wicha, "Targeting breast cancer stem cells," Molecular Oncology, vol. 4, no. 5, pp. 404-419, 2010.
154. C. Ginestier, M. H. Hur, E. Charafe-Jauffret et al., "ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome," Cell Stem Cell, vol. 1, no. 5, pp. 555-567, 2007.
155. Y. Shimono, M. Zabala, R. W. Cho et al., "Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells," Cell, vol. 138, no. 3, pp. 592-603, 2009.
156. L. Wang, D. Zhang, C. Zhang et al., "A microRNA expression signature characterizing the properties of tumor-initiating cells for breast cancer," Oncology Letters, vol. 3, no. 1, pp. 119-124, 2012.
157. Y. Wang, Y. Yu, A. Tsuyada et al., "Transforming growth factor-B regulates the sphere-initiating stem cell-like feature in breast cancer through miRNA-181 andATM," Oncogene, vol. 30,no. 12, pp. 1470-1480, 2011.
158. M. Jongen-Lavrencic, S. M. Sun, M. K. Dijkstra, P. J. M. Valk, and B. Löwenberg, "MicroRNA expression profiling in relation to the genetic heterogeneity of acute myeloid leukemia," Blood, vol. 111, no. 10, pp. 5078-5085, 2008.
159. L. Zhang, J. Huang, N. Yang et al., "microRNAs exhibit high frequency genomic alterations in human cancer," Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 24, pp. 9136-9141, 2006.
160. F. Yu, H. Yao, P. Zhu et al., "let-7 regulates self renewal and tumorigenicity of breast cancer cells," Cell, vol. 131, no. 6, pp. 1109-1123, 2007.
161. C.-J. Chang, C.-H. Chao, W. Xia et al., "P53 regulates epithelial-mesenchymal transition and stem cell properties throughmodulating miRNAs," Nature Cell Biology, vol. 13, no. 3, pp. 317-323, 2011.
162. M. Han, Y. Wang, M. Liu et al., "MiR-21 regulates epithelial-mesenchymal transition phenotype and hypoxia-inducible factor-1α expression in third-sphere forming breast cancer stem cell-like cells," Cancer Science, vol. 103, no. 6, pp. 1058-1064, 2012.
163. W. W. Hwang-Verslues, P.-H. Chang, P.-C. Wei et al., "MiR-495 is upregulated by E12/E47 in breast cancer stem cells, and promotes oncogenesis and hypoxia resistance via downregulation of E-cadherin and REDD1," Oncogene, vol. 30, no. 21, pp. 2463-2474, 2011.
164. B. Zhang, X. Pan, G. P. Cobb, and T. A. Anderson, "microRNAs as oncogenes and tumor suppressors," Developmental Biology, vol. 302, no. 1, pp. 1-12, 2007.
165. A. Gaur, D. A. Jewell, Y. Liang et al., "Characterization of microRNA expression levels and their biological correlates in human cancer cell lines," Cancer Research, vol. 67, no. 6, pp. 2456-2468, 2007.
166. S. F. Tavazoie, C. Alarcón, T. Oskarsson et al., "Endogenous human microRNAs that suppress breast cancer metastasis," Nature, vol. 451, no. 7175, pp. 147-152, 2008.
167. S. Valastyan, N. Benaich, A. Chang, F. Reinhardt, and R. A. Weinberg, "Concomitant suppression of three target genes can explain the impact of a microRNA on metastasis," Genes and Development, vol. 23, no. 22, pp. 2592-2597, 2009.
168. M. Bloomston, W. L. Frankel, F. Petrocca et al., "MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis," The Journal of the American Medical Association, vol. 297, no. 17, pp. 1901-1908, 2007.
169. Y. Liu, J. Zhao, P.-Y. Zhang et al., "MicroRNA-10b targets E-cadherin and modulates breast cancer metastasis," Medical Science Monitor, vol. 18, no. 8, pp. BR299-BR308, 2012.